Edwards Lifesciences Quarterly Cash Flow Statement
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edwards Lifesciences free cash flow
In the quarter ended Jun 30, 2026, Edwards Lifesciences generated $651.9 million of operating cash flow and spent $66.9 million on capital expenditures. That left free cash flow of $585.0 million, a free-cash-flow margin of 33.6% of revenue. Free cash flow was up 142.8% from the prior year's $240.9 million.
Edwards Lifesciences returned $153.3 million to shareholders through share repurchases, equal to 26% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Edwards Lifesciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 241.40M | 380.70M | 91.20M | 290.30M | 331.50M | 356.40M | 384.30M | 3.07B | 365.00M | 351.00M | 369.70M | 383.70M |
| Net Income growth (YoY) | -27.18% | +6.82% | -76.27% | -90.54% | -9.18% | +1.54% | +3.95% | +699.95% | +19.48% | +3.08% | -7.20% | +11.70% |
| Depreciation & Amortization | 42.70M | 40.90M | 42.70M | 39.20M | 38.10M | 36.60M | 42.60M | 34.50M | 39.60M | 38.50M | 36.70M | 36.90M |
| Stock-Based Compensation | 42.20M | 45.40M | 39.20M | 41.20M | 37.50M | 40.20M | 31.70M | 42.10M | 43.90M | 44.60M | 30.50M | 32.60M |
| Change in Working Capital | 119.50M | -475.30M | 205.90M | 223.30M | 106.50M | -136.60M | 46.90M | 23.30M | 93.60M | -186.50M | -102.20M | -58.60M |
| Operating Cash Flow | 651.90M | 43.80M | 450.90M | 573.70M | 290.20M | 280.40M | -127.50M | 351.80M | 371.50M | -53.50M | 136.60M | 411.50M |
| Capital Expenditures | -66.90M | -64.90M | -97.40M | -57.50M | -49.30M | -56.00M | -49.80M | -51.90M | -85.40M | -65.30M | -88.30M | -55.30M |
| Investing Cash Flow | -193.20M | -92.80M | -198.30M | -427.80M | -172.10M | 85.30M | -576.70M | 2.70B | 124.80M | 63.10M | 14.10M | 89.00M |
| Share Repurchases | -153.30M | -421.80M | -40.60M | -588.70M | -5.50M | -258.60M | -100.10M | -901.00M | -158.10M | -200.00K | -448.40M | -174.40M |
| Financing Cash Flow | -300.00K | -451.20M | -11.40M | -740.10M | 52.70M | -258.00M | 28.60M | -976.70M | -96.60M | 61.70M | -413.20M | -143.30M |
| Net Change in Cash | 462.20M | -492.00M | 244.70M | -595.20M | 141.20M | 90.00M | -624.60M | 2.03B | 429.10M | 81.00M | -265.90M | 366.40M |
| Free Cash Flow | 585.00M | -21.10M | 353.50M | 516.20M | 240.90M | 224.40M | -177.30M | 299.90M | 286.10M | -118.80M | 48.30M | 356.20M |
This table shows 12 quarterly periods of Edwards Lifesciences's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EW's reporting calendar. What is a cash flow statement?